Multivariable analysis for RFS and OS
| End point . | Variable . | HR . | 95% CI . | P . |
|---|---|---|---|---|
| RFS | KIT mutation | 1.67 | 0.99-2.69 | .04 |
| Log10(WBC) | 1.33 | 1.08-1.73 | .02 | |
| Trisomy 22 | 0.54 | 0.27-1.07 | .08 | |
| OS | FLT3 mutation | 2.56 | 1.15-4.85 | .006 |
| Trisomy 22 | 0.45 | 0.19-1.09 | .07 | |
| Trisomy 8 | 2.26 | 1.26-5.00 | .02 | |
| Age | 1.46* | 1.02-1.94 | .01 | |
| t-AML | 2.13 | 0.86-6.61 | .14 |
| End point . | Variable . | HR . | 95% CI . | P . |
|---|---|---|---|---|
| RFS | KIT mutation | 1.67 | 0.99-2.69 | .04 |
| Log10(WBC) | 1.33 | 1.08-1.73 | .02 | |
| Trisomy 22 | 0.54 | 0.27-1.07 | .08 | |
| OS | FLT3 mutation | 2.56 | 1.15-4.85 | .006 |
| Trisomy 22 | 0.45 | 0.19-1.09 | .07 | |
| Trisomy 8 | 2.26 | 1.26-5.00 | .02 | |
| Age | 1.46* | 1.02-1.94 | .01 | |
| t-AML | 2.13 | 0.86-6.61 | .14 |
HR greater than (less than) 1 indicates an increased (decreased) risk for the category “present” for a dichotomous variable and for a higher value of a continuous variable.
t-AML indicates therapy-related acute myeloid leukemia.
HR for difference of 10 y.